Citius Pharmaceuticals (CTXR) Competitors $1.00 +0.01 (+1.03%) Closing price 04/15/2025 04:00 PM EasternExtended Trading$0.98 -0.02 (-1.90%) As of 07:26 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock CTXR vs. PEPG, PRLD, ALVR, RNTX, IPSC, OKYO, FBRX, XLO, ELYM, and CTMXShould you be buying Citius Pharmaceuticals stock or one of its competitors? The main competitors of Citius Pharmaceuticals include PepGen (PEPG), Prelude Therapeutics (PRLD), AlloVir (ALVR), Rein Therapeutics (RNTX), Century Therapeutics (IPSC), OKYO Pharma (OKYO), Forte Biosciences (FBRX), Xilio Therapeutics (XLO), Eliem Therapeutics (ELYM), and CytomX Therapeutics (CTMX). These companies are all part of the "pharmaceutical products" industry. Citius Pharmaceuticals vs. PepGen Prelude Therapeutics AlloVir Rein Therapeutics Century Therapeutics OKYO Pharma Forte Biosciences Xilio Therapeutics Eliem Therapeutics CytomX Therapeutics PepGen (NASDAQ:PEPG) and Citius Pharmaceuticals (NASDAQ:CTXR) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their profitability, analyst recommendations, media sentiment, dividends, community ranking, risk, earnings, valuation and institutional ownership. Is PEPG or CTXR more profitable? Citius Pharmaceuticals' return on equity of -51.69% beat PepGen's return on equity.Company Net Margins Return on Equity Return on Assets PepGenN/A -60.17% -48.88% Citius Pharmaceuticals N/A -51.69%-37.60% Do insiders & institutionals have more ownership in PEPG or CTXR? 58.0% of PepGen shares are held by institutional investors. Comparatively, 16.9% of Citius Pharmaceuticals shares are held by institutional investors. 4.6% of PepGen shares are held by insiders. Comparatively, 12.1% of Citius Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. Which has more risk and volatility, PEPG or CTXR? PepGen has a beta of 1.42, indicating that its share price is 42% more volatile than the S&P 500. Comparatively, Citius Pharmaceuticals has a beta of 1.19, indicating that its share price is 19% more volatile than the S&P 500. Which has better valuation & earnings, PEPG or CTXR? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioPepGenN/AN/A-$78.63M-$2.84-0.46Citius PharmaceuticalsN/AN/A-$39.14MN/AN/A Do analysts recommend PEPG or CTXR? PepGen presently has a consensus target price of $10.33, indicating a potential upside of 688.80%. Citius Pharmaceuticals has a consensus target price of $54.50, indicating a potential upside of 5,350.00%. Given Citius Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Citius Pharmaceuticals is more favorable than PepGen.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score PepGen 1 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.33Citius Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 3.33 Does the MarketBeat Community prefer PEPG or CTXR? Citius Pharmaceuticals received 192 more outperform votes than PepGen when rated by MarketBeat users. However, 80.00% of users gave PepGen an outperform vote while only 62.54% of users gave Citius Pharmaceuticals an outperform vote. CompanyUnderperformOutperformPepGenOutperform Votes2080.00% Underperform Votes520.00% Citius PharmaceuticalsOutperform Votes21262.54% Underperform Votes12737.46% Does the media refer more to PEPG or CTXR? In the previous week, PepGen had 3 more articles in the media than Citius Pharmaceuticals. MarketBeat recorded 6 mentions for PepGen and 3 mentions for Citius Pharmaceuticals. PepGen's average media sentiment score of 0.82 beat Citius Pharmaceuticals' score of 0.30 indicating that PepGen is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment PepGen 3 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Citius Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral SummaryCitius Pharmaceuticals beats PepGen on 8 of the 13 factors compared between the two stocks. Remove Ads Get Citius Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for CTXR and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CTXR vs. The Competition Export to ExcelMetricCitius PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$8.90M$6.33B$5.33B$7.57BDividend YieldN/A3.24%5.11%4.32%P/E RatioN/A6.8121.7017.82Price / SalesN/A225.96377.7294.61Price / CashN/A65.6738.1534.64Price / Book0.125.866.464.00Net Income-$39.14M$141.86M$3.20B$247.23M7 Day Performance-4.76%4.38%2.77%1.44%1 Month Performance-33.33%-12.76%-8.60%-6.26%1 Year Performance-94.67%-11.13%10.40%0.59% Citius Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CTXRCitius Pharmaceuticals2.4088 of 5 stars$1.00+1.0%$54.50+5,350.0%-94.8%$8.90MN/A0.0020Short Interest ↑PEPGPepGen2.6692 of 5 stars$1.10+0.5%$10.33+839.4%-89.3%$35.96MN/A-0.3730Gap UpPRLDPrelude Therapeutics2.3329 of 5 stars$0.65-4.0%$4.00+517.2%-86.6%$35.75M$7M-0.36120ALVRAlloVirN/A$7.08-4.3%N/A-59.9%$35.70MN/A-0.35110RNTXRein TherapeuticsN/A$1.64-3.5%N/AN/A$35.53MN/A-0.539News CoverageGap DownIPSCCentury Therapeutics2.5948 of 5 stars$0.41-6.1%$4.40+967.7%-86.3%$35.46M$6.59M-0.22170Positive NewsOKYOOKYO Pharma3.0302 of 5 stars$1.04-8.8%$7.00+573.1%-17.0%$35.19MN/A0.007Short Interest ↓FBRXForte Biosciences2.7537 of 5 stars$5.34-9.2%$22.58+322.9%+20,463.4%$35.15MN/A-0.335Short Interest ↑Gap UpXLOXilio Therapeutics2.7958 of 5 stars$0.67-1.0%$4.00+494.4%-43.5%$34.84M$6.34M-0.3970Gap DownELYMEliem TherapeuticsN/A$1.17+1.7%N/A-72.4%$34.81MN/A-2.219CTMXCytomX Therapeutics4.0543 of 5 stars$0.43-5.3%$5.02+1,064.0%-67.9%$34.56M$138.10M2.54170Analyst ForecastNews CoverageGap Up Remove Ads Related Companies and Tools Related Companies PEPG Competitors PRLD Competitors ALVR Competitors RNTX Competitors IPSC Competitors OKYO Competitors FBRX Competitors XLO Competitors ELYM Competitors CTMX Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CTXR) was last updated on 4/16/2025 by MarketBeat.com Staff From Our PartnersHow War with China Could Start in 128 DaysThe clock is ticking. Those who aren't prepared could lose everything. I've identified 43 investments we...Behind the Markets | SponsoredThe Crypto Market is About to Change LivesI've discovered something so significant about the 2025 crypto market that I had to put everything else aside ...Crypto 101 Media | Sponsored[Action Required] Claim Your FREE IRS Loophole GuideThis shouldn't surprise anyone who's been paying attention, but... Pres. Trump may be about to unleash the ...Colonial Metals | SponsoredCrypto’s crashing…but we’re still profitingMost traders are panicking right now. Bitcoin’s dropping. Altcoins are bleeding. The stock market’s a mess....Crypto Swap Profits | SponsoredTrump’s betrayal exposed Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredIs it CRAZY to still want reliable profits, despite this market?Larry Benedict, the acclaimed "Market Wizard," is calling an emergency briefing now... The same Larry who –...Brownstone Research | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Citius Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Citius Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy CTXR Stock Free CTXR Stock Alerts